Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9599 posts found.

ARTBIO expands board and establishes technical advisory board

August 11, 2025 Medical Communications, Research and Development ARTBIO, Corporate, Oncology, advisory board, radiopharmaceuticals

ARTBIO, a radiopharma company developing radioligand therapies (RLTs), has appointed four new members to its board of directors and formed …
Appointment
pills-384846_960_720

Lilly reports positive results from trial of obesity candidate

August 8, 2025 Medical Communications, Research and Development Eli Lilly and Company, Obesity, cardiovascular risk, high blood pressure, obesity

Eli Lilly and Company (Lilly) has announced topline results from its phase 3 ATTAIN-1 trial, showing that orforglipron – a …
News

Horus Pharma expands distribution in North Africa and the Middle East

August 8, 2025 Mergers and Acquisitions, Research and Development Corporate, Horus Pharma, Opthalmology, distribution agreement

Ophthalmology company, Horus Pharma, based in Nice, France, has extended its global presence through new distribution agreements across eight countries …
News
drug-trials

Faron reports increased remission rate in trial for myelodysplastic syndrome candidate

August 7, 2025 Medical Communications, Research and Development Faron Pharmaceuticals, Oncology, US Food and Drug Administration, acute myeloid leukemia, myelodysplastic syndrome

Faron Pharmaceuticals has reported a rise in complete remission (CR) rates among patients with frontline high-risk myelodysplastic syndrome (HR-MDS) in …
News
hospital

Sanome’s AI tool gains certification for early detection of hospital infections

August 7, 2025 Business Services, Research and Development AI, Devices, Infections and infestations, Medicines and Healthcare products Regulatory Agency, NHS, Sanome, hospital-acquired infections

Sanome’s MEMORI, an artificial intelligence (AI) medical device that can predict hospital-acquired infections up to 72 hours before they present, …
News

PLL Therapeutics to present ALS research strategy at Bioshares Biotech Summit

August 7, 2025 Medical Communications, Research and Development Bioshares Biotech Summit, Neurology, PLL Therapeutics, amyotrophic lateral sclerosis, neurodegenerative diseases

French biotech, PLL Therapeutics, will present its approach to early detection and treatment of Amyotrophic Lateral Sclerosis (ALS) at the …
News
lungs

M42 study highlights positive performance of AI model for tuberculosis screening

August 6, 2025 Research and Development AI, Infections and infestations, M42, X-ray, tuberculosis

Healthcare tech company, M42, has published results from one of the largest real-world studies of an artificial intelligence (AI)-powered tuberculosis …
News
brain-770044_960_720

Lilly’s drug for early Alzheimer’s shows promising results

August 6, 2025 Medical Communications, Research and Development Alzheimer's, Eli Lilly, Neurology, dementia

Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase 3 study, showing that Kisunla …
News
blood-1813410_960_720

FDA grants orphan drug designation to relapsed or refractory multiple myeloma candidate

August 6, 2025 Medical Communications, Research and Development Oncology, Sanofi, US Food and Drug Administration, myeloma

The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, Sanofi’s investigational monoclonal antibody developed for …
News

Freya Pharma launches phase 2 study of therapy for female sexual dysfunction

August 5, 2025 Research and Development Female Sexual Interest/Arousal Disorder (FSIAD), Freya Pharma Solutions, Genito-Urinary system, sexual health

Freya Pharma Solutions has announced the initiation of a phase 2 study evaluating its Lybrido to treat female sexual interest/arousal …
News

Hansa Biopharma announces positive data for Duchenne muscular dystrophy gene therapy

August 4, 2025 Research and Development Duchenne Muscular Dystophy, Hansa Biopharma, Rare Diseases, Sarepta Therapeutics, clinical trial, genetic disorder

Hansa Biopharma has announced encouraging results from its ongoing SRP-9001-104 trial, which is investigating the use of imlifidase as a …
News

A challenge we can no longer ignore: meeting the needs of people with Crohn’s Disease in the UK

August 3, 2025 Research and Development Crohn’s disease, Immunology, Lilly UK, autoimmune disease, immunology

By Holly Thomas, Associate Vice-President Specialty Care at Lilly UK and Ireland Immunology care in the UK is at a …
Feature

Ryvu Therapeutics publishes research revealing potential drug combination for colorectal cancer

August 1, 2025 Medical Communications, Research and Development Oncology, Ryvu Therapeutics, colorectal cancer

Ryvu Therapeutics has published new findings from its ONCO Prime target discovery platform in Scientific Reports. The study reveals a …
News

Richmond Pharmacology appoints Priscilla Ochuba as associate medical director

August 1, 2025 Research and Development Contract Research Organsation, Corporate, Pharmacy, Richmond Pharmacology, associate medical director

Richmond Pharmacology has announced the promotion of Priscilla Ochuba to associate medical director, effective 1 August 2025. The move recognises …
Appointment

Labguru and Titian Software rebrand as Cenevo to accelerate connected labs

July 31, 2025 Analytical & Laboratory Services, Research and Development Cenevo, Corporate, Labguru, Laboratory management

Lab management companies, Labguru and Titian Software, have rebranded under a new unified name, Cenevo. This combines their solutions, Mosaic …
News
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026